{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:20:55Z","timestamp":1772166055872,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China, International Cooperative Research Project","award":["2023YFVA1002"],"award-info":[{"award-number":["2023YFVA1002"]}]},{"name":"Jiangsu Provincial Drug Administration Key Project","award":["202307"],"award-info":[{"award-number":["202307"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13349-6","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:24Z","timestamp":1759229904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2013benefit analysis of universal screening for HCV infection in China: a Markov modelling study"],"prefix":"10.1186","volume":"25","author":[{"given":"Dachuang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhehong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"6","key":"13349_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/microorganisms12061035","volume":"12","author":"M Sallam","year":"2024","unstructured":"Sallam M, Khalil R. Contemporary insights into hepatitis c virus: a comprehensive review. Microorganisms. 2024;12(6):1035.","journal-title":"Microorganisms"},{"issue":"2","key":"13349_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/livers4020013","volume":"4","author":"C Stasi","year":"2024","unstructured":"Stasi C, Milli C, Voller F, Silvestri C. The epidemiology of chronic hepatitis C: where we are now. Livers. 2024;4(2):172\u201381.","journal-title":"Livers"},{"issue":"5","key":"13349_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/jvh.13480","volume":"28","author":"L Krekulova","year":"2021","unstructured":"Krekulova L, Honz\u00e1k R, Riley LW. Viral hepatitis C pandemic: Challenges and threats to its elimination. J viral hepatitis. 2021;28(5):694\u20138.","journal-title":"J viral hepatitis"},{"key":"13349_CR4","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021) Results. Seattle, WA: Institute for Health Metrics an d Evaluation (IHME). 2025. Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/"},{"issue":"10","key":"13349_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14787210.2019.1675509","volume":"17","author":"M Li","year":"2019","unstructured":"Li M, Zhuang H, Wei L. How would China achieve WHO\u2019s target of eliminating HCV by 2030? Expert Rev Anti-Infe. 2019;17(10):763\u201373.","journal-title":"Expert Rev Anti-Infe"},{"issue":"5","key":"13349_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4254\/wjh.v11.i5.421","volume":"11","author":"Q Xie","year":"2019","unstructured":"Xie Q, Xuan J, Tang H, Ye X, Xu P, Lee I, Hu S. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421.","journal-title":"World J Hepatol"},{"issue":"4","key":"13349_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101000","volume":"6","author":"H Zhou","year":"2024","unstructured":"Zhou H, Yan M, Che D, Wu B. Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis. JHEP REP. 2024;6(4): 101000.","journal-title":"JHEP REP"},{"key":"13349_CR8","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. Geneva: World Health Organization. 2016."},{"key":"13349_CR9","unstructured":"World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022\u20132030: report on progress and gaps 2024. Geneva: World Health Organization; 2024."},{"key":"13349_CR10","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections: accountability for the Global Health Sector Strategies 2016\u20132021 actions for impact. Geneva: World Health Organization. 2021;1\u2013112."},{"issue":"1","key":"13349_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-024-00519-2","volume":"22","author":"Y Tu","year":"2024","unstructured":"Tu Y, Tang X, Zhou D, Shao H, Liang L, Tang W. Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C? COST EFFECT RESOUR A. 2024;22(1):11.","journal-title":"COST EFFECT RESOUR A"},{"key":"13349_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.14862","volume":"41","author":"S Pol","year":"2021","unstructured":"Pol S, Lair Mehiri L, ValletPichard A. Is elimination of HCV realistic by 2030: France. Liver Int. 2021;41:45\u20139.","journal-title":"Liver Int"},{"issue":"6","key":"13349_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2893.2009.01196.x","volume":"17","author":"E DelarocqueAstagneau","year":"2010","unstructured":"DelarocqueAstagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, RoudotThoraval F, Hillon P, Silvain C, Dhumeaux D, Desenclos JC. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepatitis. 2010;17(6):435\u201343.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"13349_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3350\/cmh.2021.0236","volume":"28","author":"H Kim","year":"2022","unstructured":"Kim H, Kim K, Choi GH, Jang ES, Ki M, Choi HY, Jeong S. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective. Clin Mol Hepatol. 2022;28(1):91\u2013104.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"13349_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","volume":"69","author":"S Deuffic-Burban","year":"2018","unstructured":"Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69(4):785\u201392.","journal-title":"J Hepatol"},{"issue":"4","key":"13349_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.37201\/req\/030.2020","volume":"33","author":"F Ledesma","year":"2020","unstructured":"Ledesma F, Buti M, Dom\u00ednguez-Hern\u00e1ndez R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. Rev Esp Quim. 2020;33(4):240\u20138.","journal-title":"Rev Esp Quim"},{"key":"13349_CR17","doi-asserted-by":"publisher","unstructured":"Wu M, Ma J, Wang X, Li S, Tan C, Xie O, Li A, Lim AG, Wan X. Cost-effectiveness and return on investment of hepatitis C virus elimination in China: a modelling study. Clin Mol Hepatol. 2025;31(2):394\u2013408. https:\/\/doi.org\/10.3350\/cmh.2024.0664. Epub 2024 Dec 3. PMID: 39623958; PMCID: PMC1201 6657.","DOI":"10.3350\/cmh.2024.0664."},{"key":"13349_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.puhe.2024.01.012","volume":"228","author":"K Fang","year":"2024","unstructured":"Fang K, Wang H, Lin Y, Zheng L, Li S, Wu J. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation. Public Health. 2024;228:186\u201393.","journal-title":"Public Health"},{"issue":"1","key":"13349_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"1","key":"13349_CR20","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jhep.2016.08.002","volume":"65","author":"PJ Easterbrook","year":"2016","unstructured":"Easterbrook PJ. WHO GDG: Who to test and how to test for chronic hepatitis C infection\u20132016 WHO testing guidance for low-and middle-income countries. J Hepatol. 2016;65(1):S46\u201366.","journal-title":"J Hepatol"},{"issue":"4","key":"13349_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2320","volume":"32","author":"PG Carty","year":"2022","unstructured":"Carty PG, McCarthy M, O\u2019Neill SM, De Gascun CF, Harrington P, O\u2019Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol. 2022;32(4): e2320.","journal-title":"Rev Med Virol"},{"issue":"1","key":"13349_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40249-024-01264-7","volume":"13","author":"A Trevi\u00f1o-Nakoura","year":"2024","unstructured":"Trevi\u00f1o-Nakoura A, Sep\u00falveda-Crespo D, Bellon JM, Codina H, Quero-Delgado M, Ryan P, Mart\u00ednez I, Resino S. Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis. Infect Dis Poverty. 2024;13(1):89.","journal-title":"Infect Dis Poverty"},{"issue":"11","key":"13349_CR23","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1002\/jmv.27157","volume":"93","author":"T Tada","year":"2021","unstructured":"Tada T, Kurosaki M, Nakamura S, Hasebe C, Kojima Y, Furuta K, Kobashi H, Kimura H, Ogawa C, Yagisawa H. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1-and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol. 2021;93(11):6247\u201356.","journal-title":"J Med Virol"},{"issue":"4","key":"13349_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","volume":"11","author":"J Xie","year":"2022","unstructured":"Xie J, Xu B, Wei L, Huang C, Liu W. Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis. Infect Dis Ther. 2022;11(4):1661\u201382.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"13349_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/17474124.2021.1963231","volume":"15","author":"C Rubino","year":"2021","unstructured":"Rubino C, Trapani S, Indolfi G. Sofosbuvir\/velpatasvir for the treatment of hepatitis C in pediatric patients. Expert Rev Gastroent. 2021;15(10):1097\u2013105.","journal-title":"Expert Rev Gastroent"},{"key":"13349_CR26","doi-asserted-by":"crossref","unstructured":"Fields MM, Chevlen E. Screening for disease: making evidence-based choices. Clin J Oncol Nurs. 2006;10(1):73.","DOI":"10.1188\/06.CJON.73-76"},{"issue":"9","key":"13349_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/djq099","volume":"102","author":"HG Welch","year":"2010","unstructured":"Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605\u201313.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"13349_CR28","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.28571","volume":"64","author":"J Chhatwal","year":"2016","unstructured":"Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64(5):1442\u201350.","journal-title":"Hepatology"},{"issue":"5","key":"13349_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","volume":"159","author":"VA Moyer","year":"2013","unstructured":"Moyer VA. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. ANN INTERN MED. 2013;159(5):349\u201357.","journal-title":"ANN INTERN MED"},{"key":"13349_CR30","doi-asserted-by":"crossref","unstructured":"Newman-Toker DE, McDonald KM, Meltzer DO: How much diagnostic safety can we afford, and how should we decide? A health economics perspective. BMJ Qual Saf. 2013;22(Suppl 2):ii11-ii20.","DOI":"10.1136\/bmjqs-2012-001616"},{"key":"13349_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-11-218","volume":"11","author":"Q Liu","year":"2011","unstructured":"Liu Q, Liu X, Jiang B, Yang W. Forecasting incidence of hemorrhagic fever with renal syndrome in China using ARIMA model. BMC INFECT DIS. 2011;11:1\u20137.","journal-title":"BMC INFECT DIS"},{"issue":"2","key":"13349_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271\u201392.","journal-title":"J Health Econ"},{"issue":"7","key":"13349_CR33","volume":"8","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Du L, Li Y, Wang L, Wang Y, Yang Y, Dong H. Cost-Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Based on Start Age and Interval in China: Modeling Study. Jmir Public Hlth Sur. 2022;8(7): e36425.","journal-title":"Jmir Public Hlth Sur"},{"issue":"1","key":"13349_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245288","volume":"16","author":"A Heffernan","year":"2021","unstructured":"Heffernan A, Ma Y, Nayagam S, Chan P, Chen Z, Cooke GS, Guo Y, Liu C, Thursz M, Zhang W, et al. Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. PLoS ONE. 2021;16(1): e0245288.","journal-title":"PLoS ONE"},{"key":"13349_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2017.05.015","volume":"43","author":"S Trippoli","year":"2017","unstructured":"Trippoli S. Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. Eur J Intern Med. 2017;43: e36.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"13349_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-1-8","volume":"1","author":"R Hutubessy","year":"2003","unstructured":"Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effect Resour A. 2003;1(1):8.","journal-title":"Cost Effect Resour A"},{"issue":"5","key":"13349_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722\u201332.","journal-title":"Med Decis Making"},{"issue":"1","key":"13349_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","volume":"8","author":"A Briggs","year":"2005","unstructured":"Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health. 2005;8(1):1\u20132.","journal-title":"Value Health"},{"key":"13349_CR39","doi-asserted-by":"publisher","unstructured":"Omar H, Elbaz T, Esmat G. Egypt: towards successful elimination of HCV in low-income countries. In: Hatzakis A, editor. Hepatitis C: epidemiology, prevention and elimination. Cham: Springer. 2021;229\u2013235. https:\/\/doi.org\/10.1007\/978-3-030-64649-3_12.","DOI":"10.1007\/978-3-030-64649-3_12."},{"issue":"5","key":"13349_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cgh.2018.08.080","volume":"17","author":"MH Eckman","year":"2019","unstructured":"Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting. Pangenotypic Treatment Regimens Clin Gastroenterol H. 2019;17(5):930\u20139.","journal-title":"Pangenotypic Treatment Regimens Clin Gastroenterol H"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13349-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:58:31Z","timestamp":1759229911000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13349"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13349-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6886757\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"1230"}}